Thermo Fisher reports high revenues in Q2

By The Science Advisory Board staff writers

July 28, 2021 -- Thermo Fisher Scientific reported a significant revenue increase during the second quarter of 2021.

For the period (end-July 3), revenue grew 34% to $9.27 billion, compared with $6.92 billion in the second quarter of 2020.

During this period, the company launched a new clinical and commercial cell therapy manufacturing facility at the University of California, San Francisco, as well as research collaboration to support the scale-up of studies and research in metabolomics. Also, Thermo Fisher brought additional capacity online to support vaccine and therapy production globally and expanded the production of laboratory plastics in North America and Europe.

After the quarter closed, the company opened a new plasmid DNA facility in California. It was opened to meet the demand for DNA-based therapies and mRNA-based vaccines, Thermo Fisher said.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here